Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

EDAP - EDAP TMS S.A. - ADR


IEX Last Trade
3.58
0.320   8.939%

Share volume: 67,905
Last Updated: Fri 30 Aug 2024 09:59:40 PM CEST
Surgical and Medical Instrument Manufacturing : -0.56%

PREVIOUS CLOSE
CHG
CHG%

$3.26
0.32
9.82%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 0%
Dept financing 0%
Liquidity 12%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
-10.62%
1 Month
-25.97%
3 Months
-37.26%
6 Months
-37.15%
1 Year
-55.14%
2 Year
-57.16%
Key data
Stock price
$3.58
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.71 - $8.50
52 WEEK CHANGE
-$0.54
MARKET CAP 
134.316 M
YIELD 
N/A
SHARES OUTSTANDING 
37.104 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
0.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$242,087
AVERAGE 30 VOLUME 
$104,565
Company detail
CEO:
Region: US
Website: edap-tms.com
Employees: 191
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke

Recent news